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Abstract
Background
Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controver-
sial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to
develop and validate a new prognostic system for patients with HCC.
Methods and Findings
Prospective collected databases from Italy (training cohort, n = 3,628; internal validation
cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop
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the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C)
using only tumor characteristics (largest tumor diameter, number of nodules, intra- and
extrahepatic macroscopic vascular invasion, extrahepatic metastases). A parametric multi-
variable survival model was then used to calculate the relative prognostic value of ITA.LI.
CA tumor stage, Eastern Cooperative Oncology Group (ECOG) performance status, Child–
Pugh score (CPS), and alpha-fetoprotein (AFP) in predicting individual survival. Based on
the model results, an ITA.LI.CA integrated prognostic score (from 0 to 13 points) was con-
structed, and its prognostic power compared with that of other integrated systems (BCLC,
HKLC, MESIAH, CLIP, JIS). Median follow-up was 58 mo for Italian patients (interquartile
range, 26–106 mo) and 39 mo for Taiwanese patients (interquartile range, 12–61 mo).
The ITA.LI.CA integrated prognostic score showed optimal discrimination and calibration
abilities in Italian patients. Observed median survival in the training and internal validation
sets was 57 and 61 mo, respectively, in quartile 1 (ITA.LI.CA score 1), 43 and 38 mo in
quartile 2 (ITA.LI.CA score 2–3), 23 and 23 mo in quartile 3 (ITA.LI.CA score 4–5), and 9
and 8 mo in quartile 4 (ITA.LI.CA score > 5). Observed and predicted median survival in the
training and internal validation sets largely coincided. Although observed and predicted sur-
vival estimations were significantly lower (log-rank test, p < 0.001) in Italian than in Taiwan-
ese patients, the ITA.LI.CA score maintained very high discrimination and calibration
features also in the external validation cohort.
The concordance index (C index) of the ITA.LI.CA score in the internal and external vali-
dation cohorts was 0.71 and 0.78, respectively. The ITA.LI.CA score’s prognostic ability was
significantly better (p < 0.001) than that of BCLC stage (respective C indexes of 0.64 and
0.73), CLIP score (0.68 and 0.75), JIS stage (0.67 and 0.70), MESIAH score (0.69 and 0.77),
and HKLC stage (0.68 and 0.75). The main limitations of this study are its retrospective
nature and the intrinsically significant differences between the Taiwanese and Italian groups.
Conclusions
The ITA.LI.CA prognostic system includes both a tumor staging—stratifying patients with
HCC into six main stages (0, A, B1, B2, B3, and C)—and a prognostic score—integrating
ITA.LI.CA tumor staging, CPS, ECOG performance status, and AFP. The ITA.LI.CA prog-
nostic system shows a strong ability to predict individual survival in European and Asian
populations.
Introduction
Liver cancer is the sixth most common cancer and the second most common cause of cancer
death worldwide, leading to nearly 746,000 deaths in 2012 [1]. Hepatocellular carcinoma
(HCC) is largely a problem in low- and middle-income countries and regions, where 83% (50%
in China alone) of the estimated 782,000 new HCC cases occurred in 2012 [1]. In addition, in
recent decades, HCC incidence and HCC-related deaths have been rising, not only in low- and
middle-income countries but also in high-income countries [2]. The highest HCC risk, mea-
sured by age-standardized rates and classified as “very high risk,” has been recorded in eastern
(31.9) and in southeastern Asia (22.2). The HCC risk in Italy (11.0) was classified as “moder-
ately high risk,” and it was one of the highest in high-income countries [1].
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Over the last 20 years, a variety of prognostic systems have been proposed in an attempt to
address the interrelationship of prognostic factors among HCC patients and the complexity of
HCC treatment [3–17]. In the literature, several HCC prognostic systems have been described
but no single system for HCC has been universally adopted. Some systems—such as Barcelona
Clinic Liver Cancer (BCLC) staging, United Network for Organ Sharing (UNOS) tumor node
metastases (TNM) staging, Hong Kong Liver Cancer (HKLC) staging, and American Joint
Committee on Cancer (AJCC) TNM staging—are “staging classification” schemas, typically
based on systematic reviews of the literature and/or expert opinions [6–9]. These systems strat-
ify the HCC population in stages exclusively or mainly defined by tumor characteristics. The
aim of these schemas is usually to link stages to guidelines for the management of patients with
HCC and the design of clinical trials. However, these systems often lack prognostic power [10]
or strong statistical support such as external validation [8].
Other systems—such as the Model to Estimate Survival in Ambulatory HCC Patients
(MESIAH), Cancer of the Liver Italian Program (CLIP), and Japanese Integrated Staging (JIS)
scores—are “conventional” prognostic scores that incorporate variables that were significant in
multivariable Cox survival analyses [11–17]. The strength of these scores consists in objective
and reproducible variables and rigorous statistical methodology. Unfortunately, even if these
prognostic scores correlate well with outcome, often they are not suitably generalizable to pop-
ulations different from the one that generated the score, and they don’t define tumor stages eas-
ily usable in clinical practice [11–17].
Based on these considerations, we sought to develop and validate a new prognostic system
for HCC patients including both a tumor staging and a prognostic score. The Italian Liver Can-
cer (ITA.LI.CA) dataset, including more than 5,000 Italian HCC patients prospectively
enrolled from 1 January 1987 to 31 March 2012, was used for the training and internal valida-
tion sets. A large HCC population from Taiwan served as the external validation cohort, to test
the prognostic value of this new system in an Asian population.
Methods
Study Groups
Prospectively collected data of 5,290 consecutive patients with HCC, each managed in one of
the 19 institutions participating in the ITA.LI.CA study group and enrolled between 1 January
1987 and 31 March 2012 were analyzed.
The institutional review boards of the participating institutions approved the study. Accord-
ing to the Italian and Taiwanese laws, no patient approval is needed for retrospective studies.
Informed consent was obtained as usual for medical, surgical, and radiological treatments, but
not specifically for patient data to be used in this retrospective study. Patients gave written con-
sent for every procedure performed in the hospitals, including use of data for medical purposes.
Details about patient data collected for this study are described in S1 Text. For each
patient the following composite variables were calculated and recorded: Child—Pugh score
(CPS), BCLC stage, UNOS modified TNM stage, HKLC stage, CLIP score, JIS stage, MESIAH
score, and modified BCLC stage [6–8,12,15,17–20]. After exclusion of 107 cases without
complete follow-up data or lost to follow-up, a total of 5,183 patients were included in the
analysis and randomly allocated into the training or test (internal validation) set in an
approximately 2:1 ratio (3,628:1,555). In addition, in order to test the general application of
our scheme to HCC patients in another center, an external validation was performed in a
cohort of 2,651 patients from Taipei (Taiwan) with HCC diagnosed between 1 January 2002
and 31 December 2012. In the Taiwanese cohort, there were no patients lost to follow-up or
with incomplete follow-up data.
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Descriptive Statistics
Baseline characteristics were examined based on frequency distribution; continuous data are
presented as median (interquartile range) unless indicated otherwise. Univariate comparisons
were assessed using Student’s t test, Wilcoxon rank-sum test, or chi-squared test as appropri-
ate. Missing data relative to study covariates always involved less than 10% of patients. Thus,
missing values were imputed using the maximum likelihood estimation method [21].
Overall survival was defined from the date of first diagnosis of HCC to the date of death, last
follow-up evaluation, or data censoring (31 December 2012). Kaplan—Meier survival curves
were used to estimate median overall survival and the 1-, 3-, and 5-y overall survival rates. The
survival curves were also stratified according to ITA.LI.CA prognostic system quartiles, and
the log-rank test was used to compare differences in survival.
Specific statistical analyses [22] were conducted to develop and validate the ITA.LI.CA
prognostic system. Here we describe only the rationale behind this process and the main statis-
tical analyses, while more statistical details are described in S2 and S3 Texts.
Development of the ITA.LI.CA Prognostic System
We first defined the ITA.LI.CA tumor staging as a composite variable based on four main
stages: 0 (very early), A (early), B (intermediate), and C (advanced) (Table 1). These stages
were similar to the BCLC stages but were designed to have some important differences from
the BCLC system so as to avoid several confusing aspects of that system. First, ITA.LI.CA
stages are based only on tumor characteristics (i.e., Eastern Cooperative Oncology Group
(ECOG) performance status test (PST) and CPS did not contribute to stage definition). Second,
single tumor>5 cm was considered B stage, regardless of the treatment received. Third, based
on published data and clinical knowledge [7,8,23], B stage patients were further stratified into
three sub-stages: B1, single HCC>5 cm or 2–3 nodules measuring 3–5 cm; B2, 2–3 nodules
measuring>5 cm or>3 nodules measuring5 cm; B3,>3 nodules measuring>5 cm or pres-
ence of intrahepatic vascular invasion. Stage C included only HCC patients with extrahepatic
vascular invasion or metastases [23].
Similar to in BCLC and HKLC staging [6,8], established variables that have determinative
roles in prognostic assessment of HCC patients—ITA.LI.CA tumor staging, CPS, ECOG PST,
Table 1. The ITA.LI.CA tumor staging system.
Diameter of the Largest Nodule
(cm)
Number of
Nodules
Vascular Invasion or
Metastases
Stage
2 1 No 0
3 2–3 No A
2–5 1 No A
3–5 2–3 No B1
>5 1 No B1
>5 2–3 No B2
5 >3 No B2
>5 >3 No B3
Any Any Intrahepatic B3
Any Any Extrahepatic C
BCLC staging [6] and UNOS modiﬁed TNM staging [7] have been taken as reference: stage 0, very early;
stage A, early; stage B, intermediate; stage C, advanced. Based on recent evidence [6,16], a sub-
classiﬁcation of stage B was introduced.
doi:10.1371/journal.pmed.1002006.t001
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and alpha-fetoprotein (AFP)—were selected a priori in building the prognostic system. AFP
was included in the ITA.LI.CA system because of its known prognostic relevance [12] and new
evidence suggesting its utility as an exclusion criterion for liver transplantation [24,25]. AFP
was added as a categorical variable (AFP> or 1,000 μg/l); 1,000 μg/l was used as the cutoff
because this value represented the AFP threshold yielding the best prognostic discrimination
in the multivariate survival model (better also than AFP used as a continuous variable).
To develop the ITA.LI.CA integrated system for individual prognostic prediction, we
selected overall survival as the outcome of interest. We therefore modeled overall survival
based on the above four prognostic factors (i.e., ITA.LI.CA tumor staging, CPS, ECOG PST,
and AFP) using a multivariable survival model to account for their relative effects.
Exploratory Analyses
As explained in S2 Text and S1 and S2 Figs, a multivariable parametric model was chosen to
construct the prognostic score in the training set.
Performance Assessment of the ITA.LI.CA Prognostic System
The performance of the ITA.LI.CA prognostic system was assessed based on a rigorous valida-
tion methodology (through internal validation and external validation in a large population
from Taiwan). To compare the prognostic performance of the ITA.LI.CA prognostic score
with that of other systems, we calculated the Akaike information criterion (AIC), the concor-
dance index (C index), and the test for trend chi-square [22,26]. The lower the AIC value, the
higher the discriminatory ability of the staging system. The higher the C index and the test for
trend chi-square, the higher the discriminatory ability and monotonicity of gradients of the
staging system. To measure whether the performance of the ITA.LI.CA score was significantly
better than that of other systems we used the likelihood ratio test.
Due to the long enrollment period (from 1987 to 2012) of the ITA.LI.CA population, a sub-
group analysis for time period was also performed, to evaluate and overcome potential time-
related biases.
Results
Characteristics of the Study Groups
The characteristics of the study groups are presented in Table 2. There were no differences in
the baseline characteristics of the training set and internal validation set. The median age of the
three groups (training, internal validation, and external validation) was 68, 67, and 65 y, respec-
tively; in all groups, there was a preponderance of male gender (75%, 76%, and 78%, respec-
tively). As expected, the majority of patients in the Taiwan validation group were hepatitis B
carriers (55%), whereas in the Italian cohort, the majority of patients were hepatitis C carriers
(61%). Liver function was better preserved in the external validation group (median Model for
End-Stage Liver Disease [MELD] score = 8) than in the Italian cohort (median MELD
score = 11). While the number of tumors was similar among the three groups, patients from
Taiwan were more likely to have larger tumors and vascular invasion. Taiwanese patients also
tended to have a high ECOG PST, compared with the two Italian sets. As expected, hepatic
resection was the most common therapeutic approach in the Taiwanese cohort [20].
The ITA.LI.CA Prognostic System
Median duration of follow-up was 58 mo for the Italian patients (interquartile range, 26–106
mo) and 39 mo for the Taiwanese patients (interquartile range, 12–61 mo). Overall survival was
New Prognostic System for Hepatocellular Carcinoma
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Table 2. Patient characteristics of the three groups.
Variable Training Set (n = 3,628) Internal Validation Set (n = 1,555) External Validation Set (n = 2,651)
Sex*
Male 2,724 (75%) 1,189 (76%) 2,054 (78%)
Female 904 (25%) 366 (24%) 597 (22%)
Age (years) 68 (60–74) 67 (61–74) 65 (55–75)
HBV+* 632 (17%) 253 (16%) 1,462 (55%)
HCV+* 2,199 (61%) 961 (62%) 812 (31%)
Alcohol abuse* 959 (26%) 417 (27%) 485 (18%)
Albumin (g/l) 36 (32–39) 35 (32–39) 37 (32–41)
Bilirubin (μmol/l)* 22.2 (15.4–32.5) 22.2 (15.4–32.5) 15.4 (10.3–23.9)
International normalized ratio* 1.3 (1.1–1.5) 1.3 (1.1–1.5) 1.1 (1–1.1)
Sodium (mmol/l) 139 (137–140) 139 (137–140) 139 (136–141)
Creatinine (μmol/l) 79.6 (70.7–97.2) 79.6 (70.7–97.2) 88.4 (70.7–106.1)
Presence of ascites* 963 (27%) 425 (27%) 645 (24%)
Presence of encephalopathy* 222 (6%) 90 (5%) 83 (3%)
AFP (μg/l)* 23 (8–100) 25 (8–113) 49 (9–860)
CPS* 6 (5–7) 6 (5–7) 5 (5–7)
MELD score* 11 (9–14) 11 (9–14) 8 (7–11)
Diameter of the largest lesion (mm)* 30 (20–43) 30 (20–46) 45 (25–90)
Multinodular (>3 nodules) 794 (22%) 347 (22%) 593 (22%)
Macroscopic vascular invasion
Any* 478 (13%) 215 (14%) 928 (35%)
Intrahepatic 211 (6%) 107 (7%) n.d.
Extrahepatic 267 (7%) 108 (7%) n.d.
Presence of metastases 95 (3%) 41 (3%) 0 (0%)
BCLC stage
0 261 (7%) 108 (7%) 162 (6%)
A* 1,181 (33%) 487 (31%) 585 (22%)
B 448 (12%) 228 (15%) 348 (13%)
C 1,511 (42%) 632 (41%) 1,170 (44%)
D* 227 (6%) 100 (6%) 385 (15%)
Modiﬁed BCLC stage
0 261 (7%) 108 (7%) 162 (6%)
A* 1,181 (33%) 487 (31%) 585 (22%)
B 1,106 (30%) 499 (32%) 823 (31%)
C 853 (24%) 361 (24%) 696 (26%)
D* 227 (6%) 100 (6%) 385 (15%)
ECOG PST
0* 2,182 (60%) 955 (61%) 1,491 (56%)
1 851 (24%) 353 (23%) 496 (19%)
2 483 (13%) 195 (13%) 335 (13%)
3–4* 112 (3%) 52 (3%) 329 (12%)
Main treatment
Resection* 392 (11%) 162 (10%) 704 (27%)
Transplantation 71 (2%) 35 (2%) 0 (0%)
Ablation* 1,073 (30%) 446 (29%) 511 (19%)
Intra-arterial therapy 944 (26%) 427 (27%) 784 (29%)
Sorafenib 112 (3%) 48 (3%) 0 (0%)
(Continued)
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significantly lower (log-rank test, p< 0.001) in the Italian patients than in the Taiwanese
patients (S3 Fig). For the Italian patients, the median overall survival was 32 mo (interquartile
range, 14–64 mo), and the 1-, 3-, and 5-y overall survival rates were 80%, 48%, and 29%, respec-
tively. For Taiwanese patients, the median overall survival was 57 mo (interquartile range, 15–
104 mo), and the 1-, 3-, and 5-y overall survival rates were 78%, 61%, and 49%, respectively.
In building the model, four main prognostic factors were selected: ITA.LI.CA tumor staging,
ECOG PST, CPS, and AFP (Table 3). These variables had the following impact in determining
the final score. For ITA.LI.CA tumor staging, one point was assigned for each increase in stage
(from 0 to 5 for 0, A, B1, B2, B3, and C). For CPS to define liver function, zero points were
assigned for a CPS of 5, one point for a CPS of 6 or 7, two points for a CPS of 8 or 9, and three
points for a CPS> 10. For ECOG PST, zero points were assigned for a PST of 0, one point for
a PST of 1–2, and three points for a PST of 3–4. CPS and PST points together formed the ITA.
LI.CA functional score. For AFP level, two points were assigned for AFP> 1,000 μg/l.
Table 2. (Continued)
Variable Training Set (n = 3,628) Internal Validation Set (n = 1,555) External Validation Set (n = 2,651)
Other systemic treatment 307 (8%) 130 (8%) 77 (3%)
Best supportive care 729 (20%) 307 (20%) 575 (22%)
Data are presented as number (percent) or median (interquartile range).
*Statistically signiﬁcant difference between the Italian (training and internal validation) and Taiwanese (external validation) study groups.
HCV+, hepatitis C virus positive; HBV+, hepatitis B virus positive; n.d., not determined.
doi:10.1371/journal.pmed.1002006.t002
Table 3. Development of the ITA.LI.CA prognostic system.
Prognostic Factor Stage, Score or Value Estimate* ± Standard Error p-Value Points**
ITA.LI.CA tumor staging 0 0 0
A 0.36 ± 0.08 <0.001 1
B1 0.48 ± 0.14 <0.001 2
B2 0.92 ± 0.21 <0.001 3
B3 1.11 ± 0.29 <0.001 4
C 1.40 ± 0.39 <0.001 5
ITA.LI.CA functional score
CPS score 5 0 0
6 0.17 ± 0.06 0.0029 1
7 0.31 ± 0.13 <0.001 1
8 0.52 ± 0.20 <0.001 2
9 0.56 ± 0.29 <0.001 2
10–15 0.75 ± 0.39 <0.001 3
ECOG PST 0 0 0
1 0.21 ± 0.05 <0.001 1
2 0.41 ± 0.12 <0.001 1
3–4 0.86 ± 0.24 <0.001 3
AFP (μg/l) 1,000 0 0
>1,000 0.59 ± 0.07 <0.001 2
*Multivariable survival parametric model estimate.
**Points = estimate × 3.5, rounded.
doi:10.1371/journal.pmed.1002006.t003
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The lowest score (ITA.LI.CA score = 0) of the model corresponded to the best prognosis,
and the highest score (ITA.LI.CA score = 13) was associated with the worst prognosis (S2
Table; p< 0.001 at log-rank test). To test the prognostic calibration of the ITA.LI.CA score,
patients were divided into quartiles at the 25th, 50th, and 75th percentiles of the risk score.
Quartile 1 coincided with ITA.LI.CA score 1, quartile 2 with score 2–3, quartile 3 with score
4–5, and quartile 4 with score> 5.
Observed median survival in the training, internal, and external validation cohort (Figs 1–3)
was 57, 61, and>129 mo, respectively, in quartile 1; 43, 38, and 75 mo, respectively, in quartile 2;
Fig 1. Expected versus observed survival in the training cohort. Patients were divided into quartiles at
the 25th, 50th, and 75th percentiles of the risk score. Quartile 1 coincided with ITA.LI.CA score 1, quartile 2
with score 2–3, quartile 3 with score 4–5, quartile 4 with score >5.
doi:10.1371/journal.pmed.1002006.g001
Fig 2. Expected versus observed survival in the internal validation cohort. Patients were divided into
quartiles at the 25th, 50th, and 75th percentiles of the risk score. Quartile 1 coincided with ITA.LI.CA
score 1, quartile 2 with score 2–3, quartile 3 with score 4–5, quartile 4 with score > 5.
doi:10.1371/journal.pmed.1002006.g002
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23, 23, and 56 mo, respectively, in quartile 3; and 9, 8, and 10 mo, respectively, in quartile 4. The
calibration was optimal in the ITA.LI.CA training and validation sets (Figs 1 and 2). In the exter-
nal validation set, calibration was better for quartiles 1 and 2 than for quartiles 3 and 4 (Fig 3).
The ITA.LI.CA score showed the best discriminatory ability and monotonicity of gradients
among the most common HCC staging systems (Table 4) in all three study cohorts (training,
internal validation, and external validation). In particular, the C index of the ITA.LI.CA score
in the internal and external validation cohorts was 0.71 and 0.78, respectively. The ITA.LI.CA
score’s prognostic ability was superior to that of BCLC stage (respective C indexes of 0.64 and
Fig 3. Expected versus observed survival in the external validation cohort. Patients were divided into
quartiles at the 25th, 50th, and 75th percentiles of the risk score. Quartile 1 coincided with ITA.LI.CA
score 1, quartile 2 with score 2–3, quartile 3 with score 4–5, quartile 4 with score > 5.
doi:10.1371/journal.pmed.1002006.g003
Table 4. Discrimination ability of the integrated ITA.LI.CA prognostic system and comparison with other staging systems in the training, internal
validation, and external validation cohorts.
HCC Staging
System
Training Cohort (n = 3,628) Internal Validation Cohort (n = 1,555) External Validation Cohort (n = 2,651)
AIC C
Index
Test for
Trend χ2
LR
Test
AIC C
Index
Test for
Trend χ2
LR
Test
AIC C
Index
Test for
Trend χ2
LR
Test
ITA.LI.CA 21,123 0.72 1,090 — 9,154 0.71 486 — 9,133 0.78 1,091 —
CLIP [12] 21,352 0.69 846 265* 9,219 0.68 390 93* 9,241 0.75 912 159*
HKLC [8] 21,408 0.68 539 297* 9,296 0.68 251 97* 9,404 0.75 621 318*
MESIAH [17] 21,516 0.69 654 415* 9,260 0.69 343 131* 9,216 0.77 731 141*
JIS [15] 21,623 0.67 588 508* 9,306 0.67 281 170* 9,691 0.70 428 610*
Modiﬁed BCLC
[20]
21,727 0.66 474 614* 9,327 0.66 231 197* 9,493 0.75 444 424*
BCLC [6] 21,857 0.65 357 745* 9,379 0.64 169 251* 9,506 0.73 407 412*
The lower the AIC value, the higher the discriminatory ability of the staging system. The higher the C index and the test for trend chi-square, the higher the
discriminatory ability and monotonicity of gradients of the staging system. The ITA.LI.CA score was compared with the other systems using the likelihood
ratio test.
*p < 0.001.
LR test, likelihood ratio test.
doi:10.1371/journal.pmed.1002006.t004
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0.73), CLIP score (0.68 and 0.75), JIS stage (0.67 and 0.70), MESIAH score (0.69 and 0.77), and
HKLC stage (0.68 and 0.75). By using the likelihood ratio test to compare different survival
models, the prognostic performance of the ITA.LI.CA system always resulted in significantly
better discrimination ability (p< 0.001) than the other systems in all three study groups. The
superiority of the ITA.LI.CA score was also confirmed after stratification of the analysis for
time period (Table 5).
Discussion
The main purpose of this study is the proposal of a new ITA.LI.CA prognostic system for HCC
including both tumor staging, with the potential to be used in the clinical management of HCC
patients, and an integrated prognostic score, to predict individual survival. This new prognostic
system has a strong prognostic ability in at least one European and one Asian population.
The ITA.LI.CA tumor staging was defined by specific stages (0, A, B1, B2, B3, and C) repre-
senting a synthesis of recent data from the literature on HCC prognosis (Table 1) [7,8,23,27].
The use of ITA.LI.CA tumor staging and CPS to develop the prognostic score was also sup-
ported by their comparison with other tumor staging and liver function assessment systems
described in the literature (S1 Table). In particular, the ITA.LI.CA tumor staging showed a
higher discrimination ability than UNOS TNM staging [7] and HKLC staging [8], and CPS had
a higher prognostic power than MELD score [28] and the new albumin—bilirubin grade [29].
The definition of some main prognostic subgroups of HCC patients (i.e., tumor stages) may
be useful to drive common therapeutic strategies or to design clinical trials [3–5]. However,
tumor staging may be inaccurate in determining individual prognosis [10]. For this reason, we
integrated the ITA.LI.CA tumor staging with CPS, ECOG PST, and AFP in a multivariable sur-
vival model to construct the ITA.LI.CA prognostic system. We investigated the discrimination
ability of the ITA.LI.CA score relative to other systems. Of note, our system showed the highest
discrimination ability in all study cohorts (Table 4). BCLC staging has been considered by
Table 5. Discrimination ability of the integrated ITA.LI.CA prognostic system and comparison with other staging systems in the training and inter-
nal validation cohorts (n = 5,183) stratified based on study period.
Period HCC Staging System AIC C Index LR Test
1987–2002 (n = 1,902) ITA.LI.CA 14,676 0.71 —
CLIP 14,805 0.68 148.13*
HKLC 14,861 0.68 195.08*
MESIAH 14,945 0.67 243.64*
JIS 14,980 0.66 320.92*
Modiﬁed BCLC 15,048 0.65 390.96*
BCLC 15,068 0.64 410.87*
2003–2012 (n = 3,281) ITA.LI.CA 15,558 0.72 —
CLIP 15,721 0.69 215.38*
HKLC 15,728 0.70 179.83*
MESIAH 15,772 0.69 285.23*
JIS 15,898 0.68 356.03*
Modiﬁed BCLC 15,952 0.68 411.35*
BCLC 16,119 0.65 578.49*
The higher the C index, the higher the discriminatory ability and monotonicity of gradients of the staging system. The ITA.LI.CA score was compared with
the other systems using the likelihood ratio test.
*p < 0.001.
LR test, likelihood ratio test.
doi:10.1371/journal.pmed.1002006.t005
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American and European guidelines to be the best system to predict survival in HCC patients
[4,5]. However, several studies have shown that this staging system has several limitations,
mainly related to the large heterogeneity of BCLC stage B and C patients [23], the controversial
prognostic role of ECOG PST [20] (which can be influenced by liver function, cancer symp-
toms, or both), and the lack of statistical weighting of different factors such as tumor status,
liver function variables, and ECOG PST [8,10]. In the current study, BCLC staging had the low-
est prognostic power among the different prognostic systems, while the ITA.LI.CA score had
the highest prognostic power (Table 4).
Therapeutic choice is probably the most important prognostic factor for HCC patients [3].
However, none of the proposed HCC prognostic systems [6–17] include this variable for two
main reasons. From a clinical point of view, treatment choice is extremely difficult to predict,
especially in HCC patients, for whom many therapies are available and many variables influ-
ence treatment decision. From a statistical point of view, there are many interactions between
therapy and other prognostic variables (i.e., tumor size and CPS influence simultaneously treat-
ment decision and survival). A potential solution to this problem is to not include treatment as
a prognostic variable, but rather consider treatment decision as an outcome variable, proposing
a treatment scheme linked to the staging system (i.e., BCLC or HKLC algorithm) [3–6,8].
Treatment algorithms, such as the BCLC and HKLC ones, however, are by nature rigid tools,
giving only one treatment option for each stage or sub-stage, and intrinsically not open to treat-
ment alternatives and evolution [23]. This difficulty explains why, in everyday clinical practice,
HCC guidelines are usually disregarded [30–35].
Based on these considerations, we deliberately did not propose a treatment algorithm in the
present study. Although this study was designed with a prognostic intent, the variables
included in the ITA.LI.CA prognostic system have an established impact on treatment deci-
sion, as recently underlined by the position paper of the Italian Association for the Study of the
Liver [28]: (a) size and number of nodules and vascular invasion (used to determine tumor
stage 0, A, B1, B2, B3, C), (b) the liver function and patient-related variables CPS and ECOG
PST (the ITA.LI.CA functional score), and (c) AFP level. In particular, the ITA.LI.CA tumor
staging preserves the basic staging system of very early (0), early (A), intermediate (B1, B2, and
B3), and advanced (C) stages, since staging according to this system is the main criterion for
treatment decisions in current guidelines. CPS and ECOG PST (composing the ITA.LI.CA
functional score) and AFP level are well known variables used to evaluate treatment feasibility
and aggressiveness within each tumor stage [3–5,28].
For clinical use, the ITA.LI.CA prognostic system can be synthetized in a single formula,
TSFA, where TS is the tumor stage, F is point value of the ITA.LI.CA functional score, and A is
the AFP point value. For example, the formula A22 indicates a patient with a stage A HCC,
with an ITA.LI.CA functional score of two points (CPS of 6–7 and PST of 1–2 or CPS of 8–9
and PST of 0), and with two points for AFP (>1,000 μg/l); the formula C00 indicates a stage C
HCC, with a CPS of 5 and a PST of 0 and with AFP 1,000. Considering that one point is
assigned to each tumor stage (Table 3, from 0 to 5 for stages from 0 to C), this simplified, user-
friendly formula can synthetize all ITA.LI.CA system components and the prognostic score,
but also provide an accurate clinical description of each HCC patient with the potential to be
used for deciding patient treatment or designing clinical trials.
Unlike other HCC prognostic scores not linked to treatment recommendations [11–17], the
ITA.LI.CA integrated prognostic system is compatible both with current guidelines [3–5,28]
and with a more modern management of HCC patients. Recent evidence, for example, sup-
ports expanded use of surgery as first-line therapy regardless of tumor status, provided that it is
technically and oncologically feasible [30–33], and the use of percutaneous ablation and intra-
arterial therapies in conjunction for early and intermediate HCCs [34,36].
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This study has several potential limitations, however. The main limitation of this study is its
retrospective nature. A prospective trial would be the ideal setting to validate the ITA.LI.CA
prognostic system. On the other hand, the high number of enrolled patients, the strong meth-
odology (internal and external validation), and the heterogeneity in treatment allocation dur-
ing the study period gave us the opportunity to compare different prognostic systems. Such a
comparison would be really difficult in a prospective trial in both ethical and statistical (sample
size) terms. Moreover, it has to be underlined that all main prognostic systems currently used
for HCC patients [6–17] were developed using retrospective series based on cohorts signifi-
cantly smaller than that used in the present study.
A second limitation concerns the intrinsically significant differences between the Taiwanese
and Italian groups (Table 2), particularly in cancer etiology, laboratory data, tumor stage distri-
bution, and, most importantly, treatment choices. In particular, we would underline the crucial
issue of differences in etiology among European and Asian countries [33,36,37]. Another
important difference between the Italian and Taiwan cohorts is the different enrollment peri-
ods. All these differences could potentially introduce selection biases. In this study, we per-
formed specific subgroup analyses showing that the prognostic power of the ITA.LI.CA
prognostic system was not influenced by enrollment period (Table 5).
The differences between the Taiwanese and Italian groups probably explain why the survival
of Taiwanese patients was significantly greater than that of Italian patients with the same ITA.
LI.CA score (Figs 1–3 and S2 Fig). On the other hand, the ITA.LI.CA system performed as the
best prognostic score also in the Taiwanese patients (Tables 4 and 5). Thus, although the Italian
and Taiwanese groups differed in their survival estimations, this study demonstrated a broad
applicability of the proposed system both in European and Asian populations.
In conclusion, the ITA.LI.CA prognostic system demonstrated the best ability of the com-
pared systems to predict the survival of Italian and Taiwanese patients. Moreover, it allows a
simple but accurate clinical description of each HCC patient, with the potential to be used for
deciding treatment or designing clinical trials.
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Editors' Summary
Background
Primary liver cancer—a tumor that starts when a liver cell acquires genetic changes that
allow it and its descendants to divide uncontrollably and move around the body (metasta-
size)—is the sixth most common cancer and the second leading cause of cancer-related
deaths worldwide. Liver cancer kills more than three-quarters of a million people every
year, mostly in resource-limited countries. The risk of developing hepatocellular carci-
noma (HCC; the most common type of liver cancer) is highest in eastern and southeastern
Asia; among wealthier nations, the risk of HCC is particularly high in Italy. HCC can be
treated by surgical removal of part of the liver, liver transplantation, ablation (which uses
an electric current to destroy the cancer cells), intra-arterial therapies (which deliver drugs
directly into the liver), or systemic (whole body) drug therapies. However, the symptoms
of HCC, which include weight loss, tiredness, and jaundice, are vague. HCC is therefore
rarely diagnosed before the cancer is advanced and has a poor prognosis (likely outcome)
—fewer than 5% of patients survive for five or more years after diagnosis.
WhyWas This Study Done?
Cancer staging describes the severity of a cancer based on the size and extent of the origi-
nal tumor and whether the tumor has metastasized. Staging helps doctors estimate the
patient’s prognosis and can help them devise a treatment plan that will, hopefully, improve
patients’ quality of life and may extend their life expectancy. Several staging systems have
been devised for HCC, but prognostic assessment of patients with HCC is controversial.
No single prognostic model (a model that allows clinicians to obtain predictions about the
likely outcomes of individual patients) has been universally adopted. An ideal model is dif-
ficult to achieve as it would need to consider tumor-related, liver-function-related, and
patient-related variables, all of which have different impacts on patient prognosis. Here,
the researchers use a database created by the Italian Liver Cancer (ITA.LI.CA) group that
includes information on more than 5,000 Italians with HCC to develop a new prognostic
model to predict individual patient outcomes based on tumor-related, liver-function-
related, and patient-related variables.
What Did the Researchers Do and Find?
The researchers first defined ITA.LI.CA stages for HCC using tumor characteristics only.
They then used information on 3,628 patients in the ITA.LI.CA database (the “training”
set) and statistical modeling to calculate the relative prognostic value of tumor staging,
Eastern Cooperative Oncology Group (ECOG) performance status (an indicator of
whether patients are able to look after themselves and undertake normal daily activities),
liver function (measured using the Child—Pugh score), and alpha-fetoprotein level (a liver
tumor marker) in the prediction of the survival of individual patients. Based on these
modeling results, they constructed an ITA.LI.CA integrated prognostic score. The
researchers report that the observed and predicted median (average) survival times in the
training set and in an internal validation cohort of 1,555 additional patients in the ITA.LI.
CA database were similar. Moreover, although the observed and predicted survival times
were lower in the Italian patients than in 2,651 patients with HCC from Taiwan, the ITA.
LI.CA score had high discrimination and calibration features in this external validation
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cohort as well (the discrimination of a prognostic model indicates its ability to separate
patients into groups with different outcomes, the calibration of a prognostic model is the
degree of correspondence between predicted and observed outcomes). Finally, the prog-
nostic ability of the new ITA.LI.CA prognostic model was significantly better than that of
several other prognostic scoring systems.
What Do These Findings Mean?
These findings introduce a revised staging system for HCC and an integrated prognostic
score—the ITA.LI.CA prognostic score—based on this staging system, Child—Pugh score,
ECOG performance status, and alpha-fetoprotein level that has a greater ability to predict
survival among Italian and Taiwanese patients than previous prognostic models. Because
this study was retrospective—previously recorded data, including outcomes, were used to
develop the prognostic model—a prospective trial is needed to validate the ITA.LI.CA
prognostic score. That is, researchers need to enroll a group of patients, determine their
ITA.LI.CA prognostic scores, and then follow the patients to determine their actual out-
comes. If validated in this way and in other populations, use of the ITA.LI.CA prognostic
score should allow clinicians to provide more accurate prognoses for individual patients,
and may be a starting point for evaluating which treatment option is best suited to each
patient presenting with HCC.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1002006.
• This study is further discussed in a PLOS Medicine Perspective by Neehar Parikh and
Amit Singal
• The US National Cancer Institute provides information about all aspects of cancer,
including detailed information for patients and professionals about primary liver cancer
and about cancer staging (in English and Spanish)
• The American Cancer Society also provides information about liver cancer (including
information on support programs and services; available in several languages)
• The UK National Health Service Choices website provides information about primary
liver cancer (including a video about coping with cancer) and about cancer staging
• Cancer Research UK (a not-for-profit organization) provides detailed information about
primary liver cancer
• The British Liver Trust (a not-for-profit organization) also provides information about
liver cancer, including a personal story
• MedlinePlus provides links to further resources about liver cancer (in English and
Spanish)
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